Literature DB >> 23617324

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.

Sally Arai1, Michelle Fanale, Sven DeVos, Andreas Engert, Tim Illidge, Peter Borchmann, Anas Younes, Franck Morschhauser, Alex McMillan, Sandra J Horning.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23617324     DOI： 10.3109/10428194.2013.798868

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  41 in total

1.  Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Robert Chen; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Dirk Huebner; Abraham Fong; Anas Younes
Journal:  Blood       Date:  2016-07-18       Impact factor: 22.113

2.  Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

Authors:  Carmelo Carlo-Stella; Francesca Ricci; Serena Dalto; Rita Mazza; Michele Malagola; Francesca Patriarca; Simonetta Viviani; Domenico Russo; Laura Giordano; Luca Castagna; Paolo Corradini; Armando Santoro
Journal:  Oncologist       Date:  2015-02-10

Review 3.  Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.

Authors:  Yun Choi; Catherine S Diefenbach
Journal:  Curr Oncol Rep       Date:  2020-01-24       Impact factor: 5.075

4.  Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Authors:  Ajay K Gopal; Robert Chen; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Xuedong Chi; Eric L Sievers; Anas Younes
Journal:  Blood       Date:  2014-12-22       Impact factor: 22.113

5.  PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.

Authors:  Beatrice Casadei; Alessandro Broccoli; Vittorio Stefoni; Cinzia Pellegrini; Miriam Marangon; Alice Morigi; Laura Nanni; Ginevra Lolli; Matteo Carella; Lisa Argnani; Michele Cavo; Pier Luigi Zinzani
Journal:  Haematologica       Date:  2019-03-19       Impact factor: 9.941

6.  A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Achim Rothe; Stephanie Sasse; Max S Topp; Dennis A Eichenauer; Horst Hummel; Katrin S Reiners; Markus Dietlein; Georg Kuhnert; Joerg Kessler; Carolin Buerkle; Miroslav Ravic; Stefan Knackmuss; Jens-Peter Marschner; Elke Pogge von Strandmann; Peter Borchmann; Andreas Engert
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

7.  A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Nancy L Bartlett; Alex F Herrera; Eva Domingo-Domenech; Amitkumar Mehta; Andres Forero-Torres; Ramon Garcia-Sanz; Philippe Armand; Sumana Devata; Antonia Rodriguez Izquierdo; Izidore S Lossos; Craig Reeder; Taimur Sher; Robert Chen; Sylvia E Schwarz; Leila Alland; Andras Strassz; Kim Prier; Cassandra Choe-Juliak; Stephen M Ansell
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

Review 8.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

9.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

10.  Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.

Authors:  Scott F Huntington; Gottfried von Keudell; Amy J Davidoff; Cary P Gross; Sapna A Prasad
Journal:  J Clin Oncol       Date:  2018-10-04       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.